{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T19:14:50Z","timestamp":1774898090752,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2023\/GNT2026992"],"award-info":[{"award-number":["2023\/GNT2026992"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Popul Health Metrics"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>NCD expenditure estimates are necessary to estimate future health system expenditure trajectories for different prevention and treatment policies. However, no dataset of comparable estimates exists across OECD countries. This study generates disease expenditure estimates for all 38 OECD member countries in 2019, for 80 major NCDs by disease phase, sex, and age group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Australian health expenditure (per person) by sex and age group was disaggregated by disease phase (first year of diagnosis, last year of life if dying of disease, otherwise prevalent) using Global Burden of Disease (GBD) data and New Zealand estimates of relative expenditure ratios by phase. These estimates were applied to GBD estimated case numbers in each OECD country and scaled to each country\u2019s total health system expenditure to estimate expenditure by NCDs in 2019. OECD purchasing power parities were used to adjust estimates to United States (US) dollars for cross-country comparability. Comparisons were made to pre-existing disease expenditure estimates for Norway, Switzerland, and the US.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Average NCD expenditure across OECD countries was US$207\u00a0million per 100,000 population. Pooled across countries, musculoskeletal disorders had the highest proportion of total health expenditure (17.4%), followed by cancer (9.4%), and cardiovascular diseases (CVD) (9.1%). Within diseases, the percentage of expenditure was higher for females for musculoskeletal disorders (56.1%), mental and substance use disorders (55.8%), and neurological conditions (54.8%). For males, it was kidney and urinary diseases (63.8%), cancer (58.3%), and CVD (50.7%). First year of diagnosis represented on average 36.8% of total NCD expenditure, while last year of life expenditure accounted for 2.6%.<\/jats:p>\n                    <jats:p>While there were similarities between our expenditure estimates and pre-existing country-specific estimates for Norway, Switzerland and the US, notable differences were observed for musculoskeletal disorders, cancer, and mental and substance use disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our estimates represent a starting point for a cross-national dataset of disease-specific expenditure that can be used to forecast future expenditure and potential health system cost savings of preventive and treatment policies. We recommend evolving our paper\u2019s methods to include multiple country-level studies as inputs \u2013 augmented by covariates (e.g. GDP, public\/private split) to better predict disease expenditure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12963-025-00418-5","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:36:43Z","timestamp":1759919803000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Estimates of non-communicable disease expenditure by disease phase, sex, and age group for all OECD countries"],"prefix":"10.1186","volume":"23","author":[{"given":"Samantha","family":"Grimshaw","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Bourke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony","family":"Blakely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"key":"418_CR1","volume-title":"Noncommunicable diseases progress monitor 2022","author":"World Health Organisation","year":"2022","unstructured":"World Health Organisation. Noncommunicable diseases progress monitor 2022. Geneva: World Health Organisation; 2022."},{"key":"418_CR2","unstructured":"Global Burden of Disease Collaborative Network. Global burden of disease study 2021 (GBD 2021). Seattle: Institute for Health Metrics and Evaluation (IHME); 2022."},{"key":"418_CR3","unstructured":"Bloom DE, et al. The global economic burden of noncommunicable Diseases. In: World economic forum. Geneva; 2011."},{"issue":"4","key":"418_CR4","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s10654-014-9984-2","volume":"30","author":"T Muka","year":"2015","unstructured":"Muka T, et al. The global impact of non-communicable diseases on healthcare spending and national income: a systematic review. Eur J Epidemiol. 2015;30(4):251\u201377.","journal-title":"Eur J Epidemiol"},{"issue":"6","key":"418_CR5","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/S2213-8587(17)30097-9","volume":"5","author":"C Bommer","year":"2017","unstructured":"Bommer C, et al. The global economic burden of diabetes in adults aged 20\u201379 years: a cost-of-illness study. Lancet Diabetes Endocrinol. 2017;5(6):423\u201330.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"45","key":"418_CR6","doi-asserted-by":"publisher","first-page":"4752","DOI":"10.1093\/eurheartj\/ehad583","volume":"44","author":"R Luengo-Fernandez","year":"2023","unstructured":"Luengo-Fernandez R, et al. Economic burden of cardiovascular diseases in the European Union: a population-based cost study. Eur Heart J. 2023;44(45):4752\u201367.","journal-title":"Eur Heart J"},{"key":"418_CR7","volume-title":"Health system spending on disease and injury in Australia 2022\u201323","author":"Australian Institute of Health and Welfare (AIHW)","year":"2024","unstructured":"Australian Institute of Health and Welfare (AIHW). Health system spending on disease and injury in Australia 2022\u201323. Canberra: AIHW, Australian Government; 2024."},{"issue":"1","key":"418_CR8","doi-asserted-by":"publisher","first-page":"e1002716","DOI":"10.1371\/journal.pmed.1002716","volume":"16","author":"T Blakely","year":"2019","unstructured":"Blakely T, et al. Health system costs for individual and comorbid noncommunicable diseases: an analysis of publicly funded health events from new Zealand. PLoS Med. 2019;16(1):e1002716.","journal-title":"PLoS Med"},{"issue":"1","key":"418_CR9","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/s12916-023-02896-6","volume":"21","author":"JM Kinge","year":"2023","unstructured":"Kinge JM, et al. Disease-specific health spending by age, sex, and type of care in Norway: a national health registry study. BMC Med. 2023;21(1):201.","journal-title":"BMC Med"},{"issue":"8","key":"418_CR10","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s10198-018-0963-5","volume":"19","author":"S Wieser","year":"2018","unstructured":"Wieser S, et al. How much does the treatment of each major disease cost? A decomposition of Swiss National health accounts. Eur J Health Econ. 2018;19(8):1149\u201361.","journal-title":"Eur J Health Econ"},{"issue":"24","key":"418_CR11","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1001\/jama.2016.16885","volume":"316","author":"JL Dieleman","year":"2016","unstructured":"Dieleman JL, et al. US spending on personal health care and public health, 1996\u20132013. JAMA. 2016;316(24):2627\u201346.","journal-title":"JAMA"},{"key":"418_CR12","unstructured":"Organisation for Economic Co-operation and, Development. Expenditure by disease, age and gender - focus on health spending. Paris; 2016."},{"key":"418_CR13","unstructured":"Australian Institute of Health and Welfare. Disease expenditure in Australia 2018-19, A.I.o.H.a. Welfare, editor. Canberra; 2021."},{"key":"418_CR14","volume-title":"Global burden of disease study 2019 (GBD 2019) disease and injury burden 1990\u20132019","author":"Global Burden of Disease Collaborative Network","year":"2020","unstructured":"Global Burden of Disease Collaborative Network. Global burden of disease study 2019 (GBD 2019) disease and injury burden 1990\u20132019. Seattle: Institute for Health Metrics and Evaluation (IHME); 2020."},{"key":"418_CR15","unstructured":"Organisation for Economic Co-operation and, Development. Health expenditure and financing, O.D. Explorer, Editor. 2025."},{"key":"418_CR16","unstructured":"Organisation for Economic Co-operation and Development. Annual Purchasing Power Parities and exchange rates, O.D. Explorer, Editor. 2025."},{"issue":"10258","key":"418_CR17","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","volume":"396","author":"T Vos","year":"2020","unstructured":"Vos T, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the global burden of disease study 2019. Lancet. 2020;396(10258):1204\u201322.","journal-title":"Lancet"},{"key":"418_CR18","volume-title":"Disease expenditure study: overview of analysis and methodology 2018\u20132019","author":"Australian Institute of Health and Welfare","year":"2021","unstructured":"Australian Institute of Health and Welfare. Disease expenditure study: overview of analysis and methodology 2018\u20132019. Canberra: Australian Institute of Health and Welfare; 2021."},{"key":"418_CR19","volume-title":"A System of Health Accounts 2011: Revised Edition","author":"Organisation for Economic Co-operation and Development, Eurostat, and World Health Organization","year":"2017","unstructured":"Organisation for Economic Co-operation and Development, Eurostat, and World Health Organization. A System of Health Accounts 2011: Revised Edition. Paris: OECD Publishing; 2017."},{"key":"418_CR20","volume-title":"Global Burden of Disease Study 2019 (GBD 2019) Demographics 1950\u20132019","author":"Global Burden of Disease Collaborative Network","year":"2020","unstructured":"Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019) Demographics 1950\u20132019. Seattle: Institute for Health Metrics and Evaluation (IHME); 2020."},{"issue":"10440","key":"418_CR21","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1016\/S0140-6736(24)00933-4","volume":"403","author":"GBD Risk Factors Collaborators","year":"2024","unstructured":"GBD Risk Factors Collaborators. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990\u20132021: a systematic analysis for the global burden of disease study 2021. Lancet. 2024;403(10440):2162\u2013203.","journal-title":"Lancet"}],"container-title":["Population Health Metrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12963-025-00418-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12963-025-00418-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12963-025-00418-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:36:49Z","timestamp":1759919809000},"score":1,"resource":{"primary":{"URL":"https:\/\/pophealthmetrics.biomedcentral.com\/articles\/10.1186\/s12963-025-00418-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["418"],"URL":"https:\/\/doi.org\/10.1186\/s12963-025-00418-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4798785\/v1","asserted-by":"object"}]},"ISSN":["1478-7954"],"issn-type":[{"value":"1478-7954","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]},"assertion":[{"value":"25 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"53"}}